A novel patient-level computational model of atrial fibrillation patterns and clinical outcomes for evaluating screening strategies

Minsi Cai, MD¹, Cristian Barrios-Espinosa, MD^{1,2}, Michiel Rienstra, MD, PhD³, Harry J.G.M. Crijns, MD, PhD¹, Ulrich Schotten, MD, PhD^{1,4}, Jordi Heijman, PhD^{1,5}

¹ Department of Cardiology, Cardiovascular Research Institute Maastricht, Faculty of Health, Medicine, and Life Sciences, Maastricht University, Maastricht, The Netherlands

² Institute of Biomedical Engineering, Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany

³ Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

⁴ Department of Physiology, Cardiovascular Research Institute Maastricht, Faculty of Health, Medicine, and Life Sciences, Maastricht University, Maastricht, The Netherlands

⁵ Gottfried Schatz Research Center, Division of Medical Physics & Biophysics, Medical University of Graz, Graz, Austria

Short title: patient-leveel modeling of atrial fibrillation

Key words: Computational modeling; Atrial fibrillation; Markov Model; Screening; Stroke

Word Count: 9607 (5968 excluding title page, references and figure legends)

Corresponding author: Jordi Heijman, PhD Gottfried Schatz Research Center, Division of Medical Physics & Biophysics, Medical University of Graz Neue Stiftingtalstr. 6; 8010 Graz, Austria Jordi.Heijman@medunigraz.at

1 Abstract

2 Background

3 The dynamic, heterogenous nature of atrial fibrillation (AF) episodes and poor symptom-rhythm

4 correlation make early AF detection challenging. The optimal screening strategy for early AF

5 detection and its role in stroke prevention in different subpopulations are unknown. We developed

- 6 a computational patient-level AF model able to simulate the dynamic occurrence of AF and AF-
- 7 associated outcomes during the entire lifetime of a virtual patient cohort to elucidate the impact of
- 8 AF screening in virtual randomized clinical trials (V-RCTs).
- 9

10 Methods

11 The Markov-like computer model has 7 clinical states (sinus rhythm, symptomatic/asymptomatic 12 AF, each with/without previous stroke, and death). AF-related atrial remodeling was incorporated, 13 which influenced the age-/sex-dependent transition probabilities between states. Model 14 calibration/validation was performed by replicating a wide range of clinical studies. AF screening

15 strategies and stroke rates in the presence of defined interventions were assessed in V-RCTs.

16

17 Results

18 The model simulates the entire lifetime of virtual patients with minute-level resolution and 19 provides perfect information on the occurrence of AF episodes and clinical outcomes (stroke, 20 death). It replicates numerous age/sex-specific episode- and population-level AF metrics, 21 including AF incidence/prevalence, progression rates, burden, episode duration, and 22 stroke/mortality incidence. The benefits of intermittent AF screening in V-RCTs were frequency-23 and duration- dependent, with systematic thrice-daily single-ECG recordings providing the highest 24 detection rates (64.6% of AF patients being diagnosed before their symptom-based clinical 25 diagnosis). Screening groups had comparable 5-year stroke rates and lower 25-year stroke rates 26 than the control group. These differences were increased by more effective anticoagulation 27 therapy, in patients with higher baseline stroke risk, or in patients with delayed clinical AF 28 diagnosis.

29

30 Conclusions

31 We present a novel computational patient-level AF model consistent with a large body of real-

world data, enabling for the first time the systematic assessment of AF-management strategies.Screening protocols with more frequent and longer monitoring have higher AF-detection rates, but

34 stroke reduction in screening-detected individuals is highly dependent on patients' and healthcare-

35 stoke reduction in screening-detected individuals is nightly dependent on patients and nearlicate-35 systems' characteristics. V-RCTs suggest that frequent AF screening with effective anticoagulation

36 can reduce stroke incidence in patients with high likelihood of delayed AF diagnosis.

38

39 Introduction

40 Atrial fibrillation (AF) is the most common cardiac arrhythmia with 59.7 million prevalent cases estimated worldwide in 2019.¹ The lifetime risk of AF for individuals with European ancestry has 41 been reported as 1 in 3 at the index age of 55 years.² The prominent increase in AF is attributable 42 43 to the growth of the aging population, increasing prevalence of comorbidities and better detection 44 opportunities.² AF is associated with higher risk of stroke/systemic embolism, heart failure, and mortality,³⁻⁵ and early detection and treatment has been shown to improve outcomes.⁶ However, 45 46 early detection and treatment of AF are challenging in clinical practice, due to the highly variable duration of AF episodes, heterogenous dynamic AF progression and poor symptom-rhythm 47 correlation.^{7,8} The optimal screening strategy to promote early AF detection and the benefits of 48 anticoagulation therapy in patients with screening-detected AF in the general population remain a 49 topic of debate.^{9,10} More studies are needed to optimize AF screening strategies, but such studies 50 are challenging due to heterogeneous risk profiles in the target population, wide range of available 51 52 monitoring devices, heterogenous AF patterns of patients, and high costs of clinical trials due to 53 the low incidence of strokes.

54

55 Computational modeling potentially offers significant advantages, including perfect control over 56 all parameters, the ability to track dynamic changes of all components, and the feasibility of 57 comprehensively assessing various interventions. There is a long-standing history of 58 computational modeling in cardiac electrophysiology with important real-world implications, including drug safety assessment and guidance of AF ablation through digital twins.^{14,15} However, 59 60 currently available mechanistic models have so far only been used for short-term simulations 61 (seconds). Health technology assessment models on the other hand are commonly used to assess 62 cost-effectiveness of therapies by simulating transitions between different clinical states, each associated with different costs and values.^{16,17} While these models allow extrapolation beyond the 63 duration of clinical trials (years) and have important implications for reimbursement decisions, 64 65 these models have so far ignored AF development, pathophysiology and progression. Here, we 66 present and validate the first computational patient-level AF model able to simulate individual AF 67 patterns, population-level AF characteristics, key pathophysiological concepts, and relevant 68 clinical outcomes during the entire lifetime of a virtual cohort. We employ this model to identify 69 effective AF screening strategies and elucidate the impact of AF screening on clinical outcomes in 70 virtual randomized clinical trials (V-RCTs).

71 Methods

72 Development of a dynamic patient-level Markov model

73 A Markov-like model was developed, comprising 7 different clinical states: sinus rhythm (SR), 74 symptomatic and asymptomatic AF (sAF and aAF, respectively), each with or without a previous 75 stroke, as well as death (Figure 1A). States were connected through age-dependent and sex-76 specific transition probabilities for AF development, conversion, incident stroke, and death. All 77 virtual patients started in the SR state at birth. During each subsequent time step (30 min, unless 78 specified otherwise), the transition probabilities toward every neighboring state were calculated. 79 Subsequently, the state for the next time step was obtained by a stochastic process in which every 80 state was chosen with likelihood corresponding to these probabilities (Figure S1). Proarrhythmic 81 AF-related atrial remodeling was incorporated through changes in three components conceptually 82 representing effective refractory period (ERP), atrial fibrosis, and atrial enlargement, which was 83 determined by the time spent in AF states and age. Being in AF states decreased the value of ERP 84 and increased the production rates of atrial fibrosis and atrial enlargement, whereas being in SR 85 states selectively reversed the ERP variable back to normal, capturing the concept of 'AF-begets-86 AF'. The relative values of the three components were used to modify the probability of AF 87 development and cardioversion. Similarly, the non-reversible probabilities of stroke and death 88 were modulated by vulnerability factors that increased when the virtual patient was in AF states 89 and continued to modulate stroke/death risks after returning to sinus rhythm. A detailed model 90 description is provided (Supplemental Methods, Table S1, Table S2, and Figure S1).

91

92 Inter-patient variability was simulated by setting the baseline risk of AF development and the 93 probability of converting to sinus rhythm to a different value for each patient at the start of the 94 simulation based on a normal distribution centered around the default parameter value, reflecting a 95 heterogeneous genetic background in the population (Table S1). In addition, virtual patients were 96 randomly assigned a male or female biological sex at the beginning of the simulation, which 97 modulated transition probabilities throughout the simulation (Supplemental Methods and Table 98 S1).

98 99

100 Model calibration and validation

101 A general overview of the model calibration strategy is depicted in Figure S2. Population-level 102 AF metrics, episode-level AF metrics, clinical outcomes, and the effects of continuous AF 103 monitoring were calibrated by reproducing study-specific patient selection criteria (e.g., matching age/sex distribution, history/type of AF, etc., see Table S3) and changing parameters to reproduce 104 105 the clinical outcomes. Subsequently, model validation with independent data not used for 106 calibration was implemented by simulating a landmark analysis of stroke risks in patients with 107 different durations of subclinical AF defined by a substudy of ASSERT (The Asymptomatic Atrial 108 Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction

- 109 Atrial Pacing Trial)¹⁸ using the final optimized parameters.
- 110

Population-level metrics: Age/sex-specific AF incidence was calculated as the number of newly
 diagnosed AF patients divided by the number of person-years of the total population within the
 age interval and sex category. Age/sex-specific AF prevalence was calculated as the number of AF

medRxiv preprint doi: https://doi.org/10.1101/2024.09.30.24314669; this version posted October 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

114 patients alive at the midpoint of an age interval divided by the total number of individuals alive at 115 this moment, for men and women. The proportion of patients with paroxysmal AF (pAF) was 116 assessed by generating a random detection timepoint. Anyone with a clinical diagnosis of 117 paroxysmal (but not persistent) AF before this timepoint would count towards the proportion of 118 pAF. These population-level metrics were calculated based on a virtual diagnosis of clinical AF, 119 consistent with the epidemiological origin of the clinical data. A virtual patient received a clinical 120 AF diagnosis in our model whenever a symptomatic AF episode reached a duration of 3 hours for 121 the first time, reflecting a lower bound on the time needed to receive medical care. The impact of 122 this healthcare system-related parameter was subsequently investigated in a sensitivity analysis 123 (discussed below). The proportion of symptomatic AF patients was calculated as the number of 124 patients with any symptomatic episodes divided by the total number of AF patients.

125

126 Episode-level metrics and progression: The average number of AF episodes per day (AF 127 frequency), the maximum duration among AF episodes (maximum duration), and the percentage

of the time in AF (AF burden) were calculated.⁸ Low/intermediate/high burden groups were 128

defined as AF burden <0.5%, 0.5%-2.5%, and >2.5% based on the RACE-V study (Interaction 129

130 Between HyperCoagulability, Electrical Remodelling, and Vascular Destabilisation in the

131 Progression of Atrial Fibrillation registry).¹⁹ Clinical AF progression rate was defined as the yearly

- 132 percentage of patients developing persistent or permanent AF. while AF burden progression rate 133 was defined as the yearly percentage of patients with an increase in AF burden >3%, based on the RACE-V study.²⁰ AF recurrence rate after spontaneous cardioversion was assessed using Kaplan-134 Meier (K-M) curves.²¹ All metrics were calibrated in virtual patients with a clinical diagnosis of 135 136 pAF selected to match the characteristics of the clinical studies. The proportion of symptomatic
- 137 AF episodes was calculated among all AF episodes of all virtual AF patients and compared to 138 clinical data from patients with CRM.
- 139

Clinical outcome metrics: Age/sex-specific all-cause mortality was calculated as the number of 140 141 new deaths divided by the number of person-years of the total population during the age range in 142 men and women. The percentage of deaths was calculated as the number of deaths within the age 143 interval divided by the total number of deaths. Similar definitions applied for age/sex-specific 144 stroke incidence and percentage of strokes. Mortality and stroke rates for specific time frames 145 were calculated as the total number of deaths and strokes during the follow-up period divided by 146 the total population at the start of follow-up. Cumulative death and stroke rates were estimated by 147 K-M curves.

148

149 **Parameter optimization**

150 Fifty-eight parameters were included in the current model (Table S1, including ones for the sex of 151 the virtual patient and screening characteristics such as frequency and duration of screening). 152 Initial values were manually chosen based on the clinical data for the aforementioned metrics and 153 a sensitivity analysis was implemented for 47 AF- and outcome-relevant parameters in order to 154 show their impact on model calibration (Supplemental Methods and Figure S3). Subsequently, 155 17 parameters were selected for further optimization using the Nelder-Mead Simplex algorithm in

- 156 Matlab R2024a (Mathworks, Natick, MA) using the difference between the metrics calculated
- 157 based on model output and the clinical data.

medRxiv preprint doi: https://doi.org/10.1101/2024.09.30.24314669; this version posted October 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

158

159 AF detection rate and incident strokes with continuous monitoring

160 The optimized model was verified by simulating the LOOP study (Atrial Fibrillation Detected by 161 Continuous ECG Monitoring Using Implantable Loop Recorder to Prevent Stroke in High-risk 162 Individuals).⁹ Based on the inclusion criteria in the LOOP study, several parameters were changed 163 to simulate the 3.25-year continuous screening (the average duration of screening) in 164 individuals >70 years with at least one additional stroke/AF risk factor but without previous stroke 165 and clinical AF, and the effect of anticoagulation therapy that could decrease the stroke probability by 70% (Table S4).^{22,23}Next, AF detection rates for specific time frames with or without CRM 166 were calculated as the total number of patients with AF episodes detected (with CRM) or newly 167 168 diagnosed clinical AF (for patients with/without CRM) during the monitoring time, divided by the 169 total population at the start of follow-up. Cumulative AF detection rates were estimated by K-M 170 curves.

171

172 Assessment of different AF screening strategies and their impact on stroke

- 173 Systematic screening protocols with different frequency and duration were designed and were
- applied to all virtual individuals from 65 years old to death, while symptom-based strategies were
- initiated after the first symptomatic AF episode after 65 years of age (independent of its duration)
- for 2 weeks (short-term symptom-based strategies) or until death (long-term symptom-based
 strategies) (Table S5). Whenever clinical AF was diagnosed before or during follow-up, screening
- 178 protocols for the virtual individual were stopped. Screening-detected AF was defined as patients
- 179 without clinical AF but with at least one AF episode detected by the screening. Earlier-detected AF
- 180 was defined as patients with screening-detected AF who also met the criteria for a subsequent
- 181 clinical AF diagnosis. In all analyses, virtual anticoagulation therapy was initiated as soon as AF
- 182 was detected by implementing a 70% reduction in the probability of stroke (i.e., parameter[51] set
- to 0.3). Subsequently, 5- or 25-year stroke rates after the initiation of AF screening were compared
- among different strategies. The effect of screening was assessed for different stroke risks
- 185 (controlled by parameter[17]), defined as baseline stroke risk and 3 times baseline stroke risk.
- Additional sensitivity analyses were conducted by changing the cutoff value for a clinical AF
- diagnosis from 3 hours to 24 hours of continuous symptomatic AF, and by increasing the efficacy
- of anticoagulation therapy from 70% to 90% less stroke incidence, reflecting potential futureadvances in anticoagulation therapy.
- 190

191 <u>Statistical description of metrics</u>

192 Five independent datasets were simulated using the optimized parameters to produce calibration

- bar plots with error bars (mean ± standard deviation) for all metrics. For K-M curves, all datasets
- were combined together and plotted with 95% confidence intervals (95% CIs) calculated by
- 195 Greenwood's method. Hazard ratios (HRs) with 95%CIs in model validation were estimated by
- 196 Cox regression. Mean relative reduction of stroke for each AF screening strategy compared with
- 197 the control group was estimated with 95% CIs using 10 simulated datasets due to the limited
- 198 number of strokes at 5-year follow-up. All K-M plots and survival analysis were conducted in
- 199 RStudio v2023.06.1 and statistical software R v4.3.0 (R core team, 2023)

201 Results

202 <u>Population-level AF metrics</u>

The patient-level model was able to simulate the entire lifetime of a virtual cohort of 10,000 individuals (50% female). During the 100-year follow-up, the virtual patients showed various AF patterns and clinical outcomes including death and stroke (top panels in **Figure 1B and 1C**). All AF episodes were captured with 30-minute-level resolution (bottom panels in **Figure 1B and 1C**), and in a subset of individuals showed the expected dynamic progression from pAF to persistent AF (**Figure 1B**).

209

210 Consistent with the known age dependence of AF risk, the AF prevalence (Figure 2A) and 211 incidence (Figure 2B) in this virtual cohort were significantly higher in older age groups. 212 Although AF incidence was numerically consistent with the range estimated from numerous studies.²⁴⁻³⁷ AF prevalence was slightly overestimated in the virtual cohort, possibly due to 213 214 underestimation of clinical AF in the real-world general population or the definition of clinical AF 215 in the model. Sex-specific AF prevalence and incidence were also calibrated and showed a similar 216 age-dependence, with both metrics significantly higher in males, especially in the older age groups (Figure S4), consistent with clinical data.^{27-31,33,35-38} The proportions of pAF (vs. non-pAF) 217 patients (Figure 2C) and symptomatic (vs. asymptomatic) AF patients (Figure 2D) were also 218 consistent with clinical data^{39,40} and accounted for around 50% and 75% of total AF patients, 219 220 respectively.

221

222 AF-episode and progression metrics

In pAF patients, the AF frequency, maximum duration of AF episodes, and AF burden during a 2week period were assessed. Although the model slightly underestimates AF frequency (Figure
3A), likely due to the temporal resolution (30 minutes) used in current simulations, the maximum
duration of AF episodes (Figure 3B) and AF burden (Figure 3C) were in good agreement with the
real data.⁸ Consistent results were also obtained specifically for male and female patients (Figure
S5).

229

We subsequently reproduced the selection criteria for early pAF from the RACE-V study.¹⁹ The resulting mean age in patients with low, intermediate, and high AF burden according to the RACE-V definition was broadly consistent with the clinical data, ranging from 62 to 68 years (**Figure 3D**), and simulated median AF burden was 0.2%, 1.0%, and 7.8% respectively (**Figure 3E**), comparable to 0.2%, 1.3% and 7.1% observed in the clinical study.¹⁹ The proportion of symptomatic AF episodes was 45%, similar to the observed data (50%) in patients with continuous monitoring (**Figure 3F**).⁴¹

AF is known as a progressive disease. While the clinical AF progression rate from pAF to persistent AF was slightly overestimated at ~4.9% / year versus 3.8% / year (**Figure 3G**),²⁰ this factor can be quite variable depending on clinical characteristics and AF detection parameters.⁴² AF burden progression rate is a more robust parameter and agreed well between simulated data (5.3% / year) and clinical data (5.5% / year; **Figure 3H**).²⁰

242

243 AF recurrence after spontaneous cardioversion varies significantly between pAF patients with

different baseline characteristics, ranging from 30%-90%.^{21,43,44} Therefore, the AF recurrence rate 244 in the virtual cohort was calibrated by reproducing baseline characteristics (age, history of AF) in 245 246 individual simulations for each clinical dataset. Different pattern of recurrent AF episodes during 247 the 28-day follow-up were documented for each virtual patient, with sparse and short episodes in 248 patients with low AF recurrence rate (Figure S6A), but frequent and relatively longer episodes in patients with higher AF recurrence rate (Figure S6B). During the 28-day follow-up, recurrent AF 249 250 episodes were detected in 60-90% of virtual patients with pAF (Figure 3I), which was in agreement with clinical data from some, but not all, randomized trials.^{21,43,44} The difference 251 between simulated recurrence and clinical data might in part be explained by the declining 252 253 patients' adherence to a full monitoring during the follow-up.⁴⁵ Together, these data confirm that 254 the model can reproduce a wide range of AF characteristics occurring during the entire lifetime of 255 a virtual population.

256

257 **Clinical outcomes**

258 AF is associated with increased morbidity and mortality, notably due to an increased risk of heart 259 failure and stroke.²⁻⁵ The ultimate goal of AF management is to improve clinical outcomes. Accordingly, we assessed clinical outcomes in individuals with or without AF in our model. 260 261 Mortality (Figure 4A), the percentage of deaths per age category (Figure 4B), stroke incidence (Figure 4C), and the percentage of strokes per age category (Figure 4D) in the virtual cohort were 262 all consistent with age-dependent data from literature.⁴⁶⁻⁴⁸ A similar age dependence was present 263 264 for both females and males, with higher risks of death (Figure S7A-D) and stroke (Figure S8A-265 **D**) in males, consistent with clinical data. Furthermore, the acute, out-of-hospital death (≤ 24 266 hours) and early-phase fatality (\leq 30 days and within 31-365 days) after stroke were reproduced for 267 the total population (Figure S9A), as well as in female (Figure S9B) and male (Figure S9C) subpopulations.49,50 268

269

270 Age- and sex-matched mortality at 15 years after AF diagnosis was approximately 25% higher in 271 simulated AF patients than in simulated individuals with SR (Figure 4E), which aligned well with 272 clinical data.⁵¹ Similarly, an almost 2-fold higher risk of cumulative incident strokes after AF diagnosis was observed in both simulated AF and clinical AF cohorts compared with those in SR 273 274 over a 3-year follow-up period (Figure 4F).⁵²

275

276 After calibrating the model to accurately reproduce these age- and sex-dependent clinical 277 outcomes, we validated the model by comparing stroke risks in patients with different durations of 278 AF episodes to a clinical dataset that was not used for parameter estimation. The simulated stroke 279 risks in patients with AF over a 3.5-year follow-up resulted in HRs of 5.40 (95%CI: 3.38-8.63), 280 2.15 (95%CI: 1.40-3.30) and 1.31 (95%CI: 0.79-2.17) compared to individuals without AF for 281 episodes of >24 hours, 6-24h and 6 minutes-6 hours, respectively. These numbers were highly 282 consistent with 5.73 (95%CI: 2.41-13.64), 1.79 (95%CI: 0.42-7.69) and 1.31 (95%CI: 0.89-5.02) observed in the ASSERT study (Figure 4G).¹⁸ These validation results highlight the model's 283 284 accuracy and predictive abilities.

285

286 Impact of different screening strategies on AF detection and stroke reduction

287 AF screening has the potential to enable early AF detection and initiation of anticoagulation

288 therapy to reduce stroke risk, but the optimal screening strategy and the benefit of anticoagulation 289 for screening-detected AF remain uncertain.^{9,10} Firstly, the model's suitability for evaluating AF screening was assessed by simulating the detection rates and benefits for stroke prevention of 290

291 CRM based on the LOOP study.⁹ Cumulative stroke rates (Figure 5A) and AF detection rates

292 (Figure 5B) reproduced in virtual CRM and control groups were highly similar to the clinical 293 data, with 5.5-year stroke rates of 4.1% and 5%, and 5.5-year AF detection rates of 29.5% and 294 16.5% in virtual CRM and control groups, respectively. This confirmed that the model can be used 295 to assess the impact of screening on AF detection and stroke reduction.

296

297 Because the follow-up time of CRM is limited by battery life and it will not be feasible to employ 298 CRM for all patients at risk of AF, we employed the model to evaluate self-defined systematic 299 (Figure 5C) and symptom-based AF screening protocols (Figure 5D and 5E). Generally, CRM 300 and intermittent strategies with higher frequency and longer monitoring periods identified more 301 AF cases from the total population (Table 1). The top 5 screening protocols that patients with AF 302 would benefit from (defined as percentage of AF patients with screening-detected AF before a 303 clinical diagnosis) were systematic CRM (99.7%, 3524 / 3534), systematic daily 3-time single 304 ECG (64.6%, 2268 / 3511, representing a smart-watch-based approach), long-term (until death) 305 symptom-based CRM (52.5%, 1852 / 3525), long-term symptom-based daily 3-time single ECG 306 (35.1%, 1217/3464), and systematic yearly 14-day Holter monitoring (23.3%, 818/3517). AF 307 could be detected earlier than the clinical diagnosis by 720 (IQR: 140, 1448), 301 (IQR: 9, 697), 308 390 (IQR: 94, 813), 204 (IQR: 11, 551), and 285 (IQR: 66, 718) days, respectively, in these 309 protocols (Table 1). Finally, we assessed the impact of the 5 screening strategies on stroke rates in 310 V-RCTs, comparing oral anticoagulation upon routine clinical AF diagnosis (control group) with 311 oral anticoagulation upon screening-detected or clinical AF. At 5-year follow-up, all strategies 312 showed similar stroke rates to the control group (Figure 6A). However, at 25-year follow-up 313 stroke rates were slightly reduced with the lowest stroke rate (5% relative risk reduction) with 314 systematic CRM (Figure 6B).

315

316 Given the limited benefits from AF screening in an unselected population, we finally performed a 317 sensitivity analysis to assess the influence of the moment of clinical AF diagnosis, the baseline 318 stroke risk, and the efficacy of anticoagulation therapy (Figure 7). The 5-year stroke rates were 319 similar in all groups and were not significantly reduced compared with the control group (all 95% 320 CIs cross the zero-effect line). However, different AF screening strategies showed distinct relative 321 stroke risk reduction at 25-year follow-up, the extent of which was sensitive to the efficacy of 322 anticoagulation therapy, baseline stroke risk, and the latency for a clinical AF diagnosis (Figure 7 323 and Figure S10-12). The largest effects were observed with systematic CRM, daily 3 times single 324 ECG, and yearly 14-day Holter groups with significant 6-12% reductions in stroke incidence 325 (Figure 7).

326 Discussion

327 We presented a novel patient-level AF model that can simulate the entire lifetime of a virtual 328 individual, capturing individual AF episodes, AF progression and relevant clinical outcomes with 329 minute-level resolution. The model incorporates key pathophysiological components, including 330 'AF begets AF' and highlights the complex, heterogeneous and dynamic development and 331 progression of AF. It reproduces many important population-level and episode-level AF 332 characteristics, including their age- and sex dependence. The model enables for the first time a 333 systematic evaluation of AF screening strategies and their impact on clinical outcomes in virtual 334 RCTs, showing huge heterogeneity in AF detection rates and identifying determinants of stroke 335 reduction when anticoagulation therapy after clinical or screening-detected AF was simulated, 336 such as the efficacy of anticoagulation therapy, the baseline stroke risk profile, and the latency of 337 clinical AF diagnoses.

338

339 <u>Computational models of atrial fibrillation</u>

340 Mechanistic modeling, data-driven modeling and health-technology assessment modeling are 341 traditionally different approaches for computational modeling of AF, each with a long history and 342 several important real-world applications, including the guidance of AF ablation using digital 343 twins, the prediction of a history of AF from a sinus rhythm ECG and the assessment of cost-344 effectiveness of novel therapies.¹⁴ However, none of these approaches have simulated AF 345 development, progression and its associated outcomes, making them unsuitable for the benefitassessment of AF screening. Chang et al. were the first to develop a patient-level Markov model 346 for the simulation of AF progression during a person's lifetime.⁵³ However, this model did not 347 include clinical outcomes and AF incidence, characteristics and progression were not calibrated 348 349 based on real-world data. Another study employed a patient-level Markov model to assess the 350 effectiveness of 45 screening strategies by simulating bleeding and stroke risks in the general 351 population. AF characteristics, common comorbidities, anticoagulation therapy, and screening 352 specificity were considered. However, no individual AF episodes were simulated, and the progressive nature due to AF-induced remodeling was ignored in these simulations.⁵⁴ To the best 353 354 of our knowledge, our model is the first to incorporate the information about every single 355 symptomatic or asymptomatic episode, together with electrical and structural remodeling of the 356 atrium and clinical outcomes during the entire lifetime with minute-level resolution, providing all 357 the components required for the systematic assessment of AF screening strategies.

358

359 Determining optimal AF screening strategies

360 The LOOP trial showed that CRM results in a >2-fold increase in AF detection.⁹ However, AF 361 screening with implantable CRM devices is not feasible in the general population. After successful 362 replication of the results from LOOP study, we therefore evaluated various self-designed AF 363 screening protocols. Our results suggest that systematic screening (assessing the whole population 364 from a certain age onwards) outperforms symptom-based screening (only starting screening in 365 individuals with suspected symptomatic AF episodes). This can be explained by the fact that 1 in 4 AF patients are totally asymptomatic and asymptomatic AF episodes account for 50% of total 366 episodes in the virtual cohort, in line with clinical data.^{39,41} On the other hand, the AF detection 367 368 rates of both systematic and symptom-based AF screening strategies are frequency- and duration-

dependent in the simulation, which is consistent with previous simulation data⁵⁵ and suggests a 369 370 need for long-term monitoring for better AF diagnosis. This idea is supported by a recent RCT that 371 one-time single-lead ECG screening at 65 years or older does not increase the rate of new AF diagnosis significantly in primary-care settings.⁵⁶ Of note, longer total screening time is not 372 373 associated with higher AF detection rates. For example, systematic daily 3-times 1-min ECG 374 (1095 minutes per year) detects more AF patients than a systematic yearly 14-day Holter (20160 375 minutes per year). This result is likely due to the typical patterns of AF development, often 376 beginning with sporadic and short-lasting AF episodes and then progressing to more frequent and 377 longer AF episodes during the follow-up (Figure 1B and 1C). In the current simulation, AF 378 screening will be initiated at 65 years, when most virtual patients are most likely in the early phase 379 of AF development. Thus, different screening strategies may capture this dynamic AF progression 380 with heterogenous sensitivity. Our results indicate that heterogenous AF development and 381 progression in the target population should be considered when choosing the best AF screening 382 strategy. Long-term short, frequent monitoring facilitated by developments in single-lead ECG 383 hardware, e.g., in smart-watch devices, may be more sensitive to identify sparse AF episodes. The 384 feasibility of AF screening with consumer devices has been validated in the general population, 385 showing improved anticoagulation therapy, rate- or rhythm-control strategies and risk factor 386 management in diagnosed AF patients.⁵⁷

387

388 Potential benefits of AF screening and anticoagulation therapy

389 After the evaluation of AF detection rates of different screening strategies, we evaluated the 390 potential benefits of virtual anticoagulation therapy for screening-detected AF. The 5-year stroke 391 rates are similar between control and screening groups, and only systematic CRM shows slight 392 relative stroke risk reduction during long-term (25-year) follow-up in the unselected baseline 393 population over 65 years of age. These results are consistent with recent RCTs which have shown 394 small net reduction or no reduction in stroke despite increased AF diagnosis in individuals with 395 extra stroke risks but without previous AF diagnosis undergoing intermittent screening or CRM during 5-7 years follow-up.^{9,10} These results support the idea that although AF screening will 396 397 identify more AF cases and lead to earlier anticoagulation therapy, benefits of AF screening in 398 terms of stroke reduction may still be limited, even when long-term CRM is used. Considering the significantly higher risk of major bleeding in patients with device-detected subclinical AF and 399 anticoagulation therapy¹³ and the potential costs of such a screening strategy, screening for 400 401 everyone is likely not the best choice. We therefore employed the model to evaluate parameters 402 that may affect the benefit of AF screening.

403

404 In our sensitivity analysis, patients with more effective anticoagulation therapy, higher baseline 405 stroke risk, and higher likelihood of delayed clinical AF diagnosis, e.g., due to poor ad-hoc 406 accessibility to cardiology care (simulated by prolonged AF-duration criteria for clinical AF 407 diagnosis), the reduction of 25-year stroke rates was more significant, particularly in CRM and 408 systematic screening groups (Figure 6, Figure 7, and Figure S10-S12). Thus, our approach 409 suggests that tailored systematic screening approaches in selected settings could be beneficial. 410 One recent population-level simulation has indicated that AF screening can result in quality-411 adjusted life-year gains and a reduction in stroke risks, which varies significantly and is highly dependent on specific combinations of strategies used.⁵⁴ Of note, most current AF-screening 412

413 studies, including our simulations, have only evaluated the screening-enabled benefits of 414 anticoagulation therapy, whereas a systematic evaluation of the combined effects with other 415 interventions such as rhythm control and upstream treatments has not been performed.

416

417 **Potential limitations**

418 Although age, the most important risk factor for AF development, and sex have been explicitly 419 included in the model, other known AF risk factors such as hypertension and heart failure are only 420 incorporated implicitly by reproducing epidemiological data sets. In particular, the model captures 421 the age dependence of AF-development and mortality. Virtual individuals that develop AF or die at 422 a young age likely implicitly represent those people with a higher burden of risk factors and 423 comorbidities, even when these are not modelled explicitly. Nevertheless, the absence of these 424 components can make the exact replication of inclusion criteria in different studies challenging. 425 We have tried to simulate the study-specific patient selection as much as possible based on age. 426 sex, AF history and clinical priors (Table S3). While the model is generally consistent with a wide 427 range of clinical data, some quantitative differences exist and may be due to this patient selection. 428 On the other hand, results from clinical studies may also be biased due to various practical issues 429 during the implementation. For example, a lack of patients' adherence to full monitoring during the 4-week follow-up after spontaneous cardioversion was reported.⁴⁵ but without sufficient detail 430 431 to reproduce in the model, potentially contributing to the mismatch between simulated and 432 observed AF recurrence rates (red line and triangles in Figure 3I). In addition, the model uses a 433 temporal resolution of 30 minutes for computational efficiency. As such, short episodes of micro-434 AF cannot be simulated, potentially contributing to the underestimation of the AF frequency 435 (Figure 2A). However, the clinical relevance of such short-lived episodes remains uncertain at 436 present. Finally, only stroke and death were incorporated as clinical outcomes in our model. Thus, 437 safety analyses, e.g., in terms of bleeding risk after starting anticoagulation in screening-detected AF,¹³ and risk-benefit assessment cannot be simulated in the current V-RCTs and should be 438 439 considered in future research. Nevertheless, our simulation results are consistent with the limited 440 short-term efficacy of oral anticoagulation therapy for screening-detected AF reported in recent 441 trials. They also help to identify conditions when AF screening may benefit long-term outcomes, 442 which will ultimately need to be validated in a real-world RCT.

443

444 **Future perspectives**

445 The current computational patient-level AF model provides perfect control over every component 446 responsible for AF development, progression and relevant clinical outcomes and can reproduce 447 numerous population-level metrics and essential clinical characteristics of AF during the entire 448 lifetime of a virtual patient. As such, the model is expected to be helpful for future mechanistic 449 studies on AF development, evaluating AF pattern changes and progression, predicting long-term 450 clinical prognosis, and assessing the efficacy of different treatments in different populations. As 451 such, the model may provide valuable information for the design and statistical power estimation 452 of future RCTs, potentially helping to overcome gender disparities by explicitly addressing sex 453 differences and enabling studies with equal representation of men and women. Finally, it provides 454 a foundation for follow-up studies into the role of different risk factors, making it a valuable tool 455 to analyze personalized holistic AF management without any costs. We have made the model and 456 source code freely available on https://github.com/HeijmanLab/ to allow others to use and

457 expand this novel approach.

458

459 Conclusions

460 We developed a novel patient-level AF model that captures the individual dynamic AF 461 development and progression during the entire lifetime of a virtual patient. The model reproduces 462 many important clinical characteristics and population-level metrics of AF in virtual cohorts. V-463 RCTs simulated by the model revealed how different AF screening strategies can result in 464 heterogenous AF detection rates and benefits for stroke reduction, highlighting potential benefits 465 of AF screening combined with anticoagulation therapy in populations suspected of delayed AF 466 diagnosis. The novel patient-level AF model is expected to enable future studies in the field of 467 basic mechanisms, risk stratification and comprehensive management of AF.

468

469 Acknowledgements

- 470 The authors thank Adele Benzoni, Eva Schuijt, Fateme Farahani, and Paul Volders for helpful
- discussions.

472 Sources of funding

473 The current work is funded by the Cardiovascular Research Institute Maastricht (CARIM PhD call 474 2020 to J.H.), the European Union (MAESTRIA: Machine Learning Artificial Intelligence Early 475 Detection Stroke Atrial Fibrillation, grant number 965286 to U.S.), the Netherlands Organization 476 for Scientific Research (NWO/ZonMW Vidi 09150171910029 to J.H.) and the Dutch Heart 477 Foundation (CVON2014-09, RACE V Reappraisal of Atrial Fibrillation: Interaction between 478 hyperCoagulability, Electrical remodeling, and Vascular Destabilisation in the Progression of AF 479 to H.C., M.R., and U.S. and Grant number 01-002-2022-0118, EmbRACE consortium to M.R., 480 U.S. and J.H.).

481 Disclosures

U.S. received consultancy fees or honoraria from Università della Svizzera Italiana (USI,
Switzerland), Roche Diagnostics (Switzerland), EP Solutions Inc. (Switzerland), Johnson &
Johnson Medical Limited, (United Kingdom), Bayer Healthcare (Germany). U.S. is co-founder
and shareholder of YourRhythmics BV, a spin-off company of the University Maastricht. The
other authors have nothing to declare.

487 Supplemental material

- 488 Supplemental methods and steps of sensitivity analysis
- 489 Table S1. Values and Sigma of parameters used in the current model.

- **490** Table S2. Initial values of different states in the model.
- 491 Table S3. Values and Sigma of parameters changed for LOOP study calibration.
- **492** Table S4 Parameters setting for the simulation of different AF screening protocols.
- 493 Table S5 The detailed information for study-specific model calibration and model validation
- 494 Figure S1. The schematic flowchart showing how the states transition runs in the patient-level AF495 model.
- 496 Figure S2. The workflow for model development, calibration, validation and subsequent
- 497 application.
- 498 Figure S3. Sensitivity analysis showing the impacts of individual model parameters on different499 model outcomes.
- 500 Figure S4. The age-dependent and sex-specific prevalence and incidence of clinical atrial
- 501 fibrillation (AF).
- 502 Figure S5. Sex-specific atrial fibrillation (AF) episode characteristics.
- Figure S6. Atrial fibrillation (AF) recurrence plots during a 4-week follow-up after spontaneouscardioversion.
- Figure S7. The age-dependent and sex-specific mortality and percentage of deaths across differentage groups.
- Figure S8. The age-dependent and sex-specific stroke incidence and percentage of strokes acrossdifferent age groups.
- 509 Figure S9. The percentage of deaths prehospital (simulated as the first 24 hours), within the first
- 510 month, or within the first year after stroke compared with data from clinical studies.
- 511 Figure S10. Comparison of 5-year and 25-year stroke rates in populations with or without atrial
- 512 fibrillation (AF) screening with 3-hour diagnostic criteria for clinical AF, EFFICACY OF
- 513 ANTICOAGULATION THERAPY AS 90% LESS STROKE INCIDENCE, and normal baseline
- 514 stroke rates.
- 515 Figure S11. Comparison of 5-year and 25-year stroke rates in populations with or without atrial
- 516 fibrillation (AF) screening with 3-hour diagnostic criteria for clinical AF, efficacy of
- anticoagulation therapy as 70% less stroke incidence, and 3-FOLD INCREASED BASELINE
- 518 STROKE RATES.
- 519 Figure S12. Comparison of 5-year and 25-year stroke rates in populations with or without atrial
- 520 fibrillation (AF) screening with 24-HOUR DIAGNOSTIC CRITERIA FOR CLINICAL AF,
- 521 efficacy of anticoagulation therapy as 70% less stroke incidence, and normal baseline stroke rates.
- 522

medRxiv preprint doi: https://doi.org/10.1101/2024.09.30.24314669; this version posted October 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

523 References 524 Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, 1. 525 Beaton AZ, Benjamin EJ, Benziger CP, et al. Global Burden of Cardiovascular Diseases and Risk 526 Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76:2982-3021. 527 doi: 10.1016/j.jacc.2020.11.010 528 Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, Boriani G, Castella 2. 529 M, Dan GA, Dilaveris PE, et al. 2020 ESC Guidelines for the diagnosis and management of atrial 530 fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery 531 (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European 532 Society of Cardiology (ESC) Developed with the special contribution of the European Heart 533 Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373-498. doi: 534 10.1093/eurheartj/ehaa612 535 Ziff OJ, Carter PR, McGowan J, Uppal H, Chandran S, Russell S, Bainey KR, Potluri R. The 3. 536 interplay between atrial fibrillation and heart failure on long-term mortality and length of stay: 537 Insights from the, United Kingdom ACALM registry. Int J Cardiol. 2018;252:117-121. doi: 538 10.1016/j.ijcard.2017.06.033 539 4. Ceornodolea AD, Bal R, Severens JL. Epidemiology and Management of Atrial Fibrillation and 540 Stroke: Review of Data from Four European Countries. Stroke Res Treat. 2017;2017:8593207. 541 doi: 10.1155/2017/8593207 542 Magnussen C, Niiranen TJ, Ojeda FM, Gianfagna F, Blankenberg S, Njolstad I, Vartiainen E, Sans 5. 543 S, Pasterkamp G, Hughes M, et al. Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the 544 545 BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). 546 Circulation. 2017;136:1588-1597. doi: 10.1161/CIRCULATIONAHA.117.028981 547 Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase 6. 548 D, Haegeli LM, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J 549 Med. 2020;383:1305-1316. doi: 10.1056/NEJMoa2019422 550 Hermans ANL, Pluymaekers N, Lankveld TAR, van Mourik MJW, Zeemering S, Dinh T, den Uijl 7. 551 DW, Luermans J, Vernooy K, Crijns H, et al. Clinical utility of rhythm control by electrical 552 cardioversion to assess the association between self-reported symptoms and rhythm status in 553 patients with persistent atrial fibrillation. Int J Cardiol Heart Vasc. 2021;36:100870. doi: 554 10.1016/j.ijcha.2021.100870 555 Wineinger NE, Barrett PM, Zhang Y, Irfanullah I, Muse ED, Steinhubl SR, Topol EJ. 8. 556 Identification of paroxysmal atrial fibrillation subtypes in over 13,000 individuals. Heart Rhythm. 557 2019;16:26-30. doi: 10.1016/j.hrthm.2018.08.012 558 Svendsen JH, Diederichsen SZ, Hojberg S, Krieger DW, Graff C, Kronborg C, Olesen MS, 9. 559 Nielsen JB, Holst AG, Brandes A, et al. Implantable loop recorder detection of atrial fibrillation to 560 prevent stroke (The LOOP Study): a randomised controlled trial. Lancet. 2021;398:1507-1516. 561 doi: 10.1016/S0140-6736(21)01698-6 562 10. Svennberg E, Friberg L, Frykman V, Al-Khalili F, Engdahl J, Rosenqvist M. Clinical outcomes in

- 563 systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group,
 564 unmasked, randomised controlled trial. *Lancet.* 2021;398:1498-1506. doi: 10.1016/S0140565 6736(21)01637-8
- 566 11. Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF, Atar D, Birnie DH,

567		Boriani G, Camm AJ, et al. Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. N
568		Engl J Med. 2023. doi: 10.1056/NEJMoa2310234
569	12.	Kirchhof P, Toennis T, Goette A, Camm AJ, Diener HC, Becher N, Bertaglia E, Blomstrom
570		Lundqvist C, Borlich M, Brandes A, et al. Anticoagulation with Edoxaban in Patients with Atrial
571		High-Rate Episodes. N Engl J Med. 2023;389:1167-1179. doi: 10.1056/NEJMoa2303062
572	13.	McIntyre WF, Benz AP, Becher N, Healey JS, Granger CB, Rivard L, Camm AJ, Goette A, Zapf
573		A, Alings M, et al. Direct Oral Anticoagulants for Stroke Prevention in Patients with Device-
574		Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESIA
575		Trials. Circulation. 2023. doi: 10.1161/CIRCULATIONAHA.123.067512
576	14.	Heijman J, Sutanto H, Crijns H, Nattel S, Trayanova NA. Computational models of atrial
577		fibrillation: achievements, challenges, and perspectives for improving clinical care. Cardiovasc
578		<i>Res.</i> 2021;117:1682-1699. doi: 10.1093/cvr/cvab138
579	15.	Travanova NA, Lvon A, Shade J, Heijman J, Computational modeling of cardiac
580		electrophysiology and arrhythmogenesis: toward clinical translation. <i>Physiol Rev.</i> 2024;104:1265-
581		1333 doi: 10.1152/physrev.00017.2023
582	16	Lyth J. Svennberg F. Bernfort L. Aronsson M. Frykman V. Al-Khalili F. Friberg L. Rosenqvist M.
583	10.	Engdahl J Levin LA Cost-effectiveness of population screening for atrial fibrillation: the
584		STROKESTOP study Fur Heart I 2023:44:196-204 doi: 10.1093/eurhearti/ebac547
585	17	Aronsson M. Svennberg F. Rosenqvist M. Engdahl I. Al-Khalili F. Friberg I. Frykman-Kull V.
586	17.	Levin I.A. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent
587		ECG recording Europace 2015:17:1023-1029 doi: 10.1093/europace/euv083
588	18	Van Gelder IC Healey IS Crijns H Wang I Hohnloser SH Gold MR Capucci A Lau CP
589	10.	Morillo CA Hobbelt AH et al Duration of device-detected subclinical atrial fibrillation and
590		occurrence of stroke in ASSERT Fur Heart I 2017:38:1330 1344 doi: 10.1003/eurhearti/ebv042
591	10	De With PR Erkuner O Bienstra M Nauven BO Korver FWI Linz D Cate Ten H Spronk H
502	19.	Kroon AA Mass AH at al Temporal patterns and short term progression of parovusmal atrial
592		fibrillation: data from PACE V. Europage 2020:22:1162-1172 doi: 10.1002/europage/eur
501	20	Normanon. data nom KACE V. Europuce. 2020,22.1102-1172. doi: 10.1095/europace/eular25
505	20.	P. Al lazoiri M. Maaga A.H. et al. Provalance and determinents of strial fibrillation programsion in
596		R, AI-Jazah W, Maass AH, et al. Hevalence and determinants of atrial normation progression in percevicing strial fibrillation. <i>Heart</i> , 2022;100:186–104. doi: 10.1136/heartinl.2022.321027
507	21	Diverselers N. Dudiek F. Lyarmans I. Madan IC. Londonink T. Widdershavan I. Duay III.
221	21.	Playmaekers N, Dudink E, Luermans J, Meeder JG, Lenderink I, Widdersnoven J, Bucx JJJ,
590		Atrial Eibrillation, NEucl. 1 Mar. 2010;280:1400, 1508, doi: 10.1056/DEDMar.1000252
233	22	Autai Fiormation. N Engl 5 Med. 2019;580:1499-1508. doi: 10.1050/NEJMoa1900555
601	22.	Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antimrombolic therapy to prevent stroke in
601		patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867. doi:
602 C02	22	10./320/0003-4819-146-12-200/06190-0000/
603	23.	Ruff CI, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ,
604 COF		weitz JI, Lewis BS, Parknomenko A, et al. Comparison of the efficacy and safety of new oral
605		anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised
606	~ (trials. <i>Lancet</i> . 2014;383:955-962. doi: 10.1016/S0140-6736(13)62343-0
607	24.	Bonhorst D, Mendes M, Adragao P, De Sousa J, Primo J, Leiria E, Rocha P. Prevalence of atrial
608		tibrillation in the Portuguese population aged 40 and over: the FAMA study. <i>Rev Port Cardiol</i> .
609	• -	2010;29:331-350.
610	25.	Lake FR, Cullen KJ, de Klerk NH, McCall MG, Rosman DL. Atrial fibrillation and mortality in

611 elderly population. Aust N Z J Med. 1989;19:321-326. doi: 10.1111/j.1445an 612 5994.1989.tb00271.x

- 613 26. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the 614 Framingham Study. Stroke. 1991;22:983-988. doi: 10.1161/01.str.22.8.983
- 615 27. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and 616 flutter in the United States. Am JCardiol. 2009;104:1534-1539. doi: 617 10.1016/j.amjcard.2009.07.022
- 618 28. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of 619 diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke 620 prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 621 2001;285:2370-2375. doi: 10.1001/jama.285.18.2370
- 622 29. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. 623 Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and 624 implications on the projections for future prevalence. Circulation. 2006;114:119-125. doi: 625 10.1161/CIRCULATIONAHA.105.595140
- 626 Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: Incidence, prevalence, and 30. 627 prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, 628 and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J. 629 2008;156:57-64. doi: 10.1016/j.ahj.2008.03.010
- 630 31. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip 631 GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam 632 study. Eur Heart J. 2006;27:949-953. doi: 10.1093/eurheartj/ehi825
- 633 32. Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in 634 general practice in England and Wales, 1994-1998: analysis of data from the general practice 635 research database. Heart. 2001;86:284-288. doi: 10.1136/heart.86.3.284
- 636 33. Murphy NF, Simpson CR, Jhund PS, Stewart S, Kirkpatrick M, Chalmers J, MacIntyre K, 637 McMurray JJ. A national survey of the prevalence, incidence, primary care burden and treatment 638 of atrial fibrillation in Scotland. Heart. 2007;93:606-612. doi: 10.1136/hrt.2006.107573
- 639 34. Piccini JP, Hammill BG, Sinner MF, Jensen PN, Hernandez AF, Heckbert SR, Benjamin EJ, 640 Curtis LH. Incidence and prevalence of atrial fibrillation and associated mortality among 641 Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes. 2012;5:85-93. doi: 642 10.1161/CIRCOUTCOMES.111.962688
- 643 35. Chugh SS, Havmoeller R, Naravanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, 644 McAnulty JH, Jr., Zheng ZJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden 645 Disease 2010 2014;129:837-847. of Study. Circulation. doi: 646 10.1161/CIRCULATIONAHA.113.005119
- 647 36. Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, Maywald U, Bauersachs R, 648 Breithardt G. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million 649 patients. Europace. 2013;15:486-493. doi: 10.1093/europace/eus333
- 650 37. Dong XJ, Wang BB, Hou FF, Jiao Y, Li HW, Lv SP, Li FH. Global burden of atrial 651 fibrillation/atrial flutter and its attributable risk factors from 1990 to 2019. Europace. 652 2023;25:793-803. doi: 10.1093/europace/euac237
- 653 38. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, Folsom AR. 654 Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in

655 Communities (ARIC) study. Am Heart J. 2009;158:111-117. doi: 10.1016/j.ahj.2009.05.010

- Gibbs H, Freedman B, Rosenqvist M, Virdone S, Mahmeed WA, Ambrosio G, Camm AJ,
 Jacobson B, Jerjes-Sanchez C, Kayani G, et al. Clinical Outcomes in Asymptomatic and
 Symptomatic Atrial Fibrillation Presentations in GARFIELD-AF: Implications for AF Screening. *Am J Med.* 2021;134:893-901 e811. doi: 10.1016/j.amjmed.2021.01.017
- 40. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, Cobbe S, Breithardt G,
 Le Heuzey JY, Prins MH, et al. Atrial fibrillation management: a prospective survey in ESC
 member countries: the Euro Heart Survey on Atrial Fibrillation. *Eur Heart J.* 2005;26:2422-2434.
 doi: 10.1093/eurheartj/ehi505
- 41. Verma A, Champagne J, Sapp J, Essebag V, Novak P, Skanes A, Morillo CA, Khaykin Y, Birnie
 D. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation
 before and after catheter ablation (DISCERN AF): a prospective, multicenter study. *JAMA Intern Med.* 2013;173:149-156. doi: 10.1001/jamainternmed.2013.1561
- 42. Heijman J, Luermans J, Linz D, van Gelder IC, Crijns H. Risk Factors for Atrial Fibrillation
 Progression. *Card Electrophysiol Clin.* 2021;13:201-209. doi: 10.1016/j.ccep.2020.10.011
- 670 43. Pritchett EL, DaTorre SD, Platt ML, McCarville SE, Hougham AJ. Flecainide acetate treatment of
 671 paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies.
 672 The Flecainide Supraventricular Tachycardia Study Group. *J Am Coll Cardiol*. 1991;17:297-303.
 673 doi: 10.1016/s0735-1097(10)80090-7
- 44. Atarashi H, Ogawa S, Inoue H, Hamada C, Flecainide Atrial Fibrillation I. Dose-response effect
 of flecainide in patients with symptomatic paroxysmal atrial fibrillation and/or flutter monitored
 with trans-telephonic electrocardiography: a multicenter, placebo-controlled, double-blind trial. *Circ J.* 2007;71:294-300. doi: 10.1253/circj.71.294
- 45. van der Velden RMJ, Pluymaekers N, Dudink E, Luermans J, Meeder JG, Heesen WF, Lenderink
 T, Widdershoven J, Bucx JJJ, Rienstra M, et al. Mobile health adherence for the detection of
 recurrent recent-onset atrial fibrillation. *Heart*. 2022;109:26-33. doi: 10.1136/heartjnl-2022321346
- 46. Modig K, Talback M, Ziegler L, Ahlbom A. Temporal trends in incidence, recurrence and
 prevalence of stroke in an era of ageing populations, a longitudinal study of the total Swedish
 population. *BMC Geriatr.* 2019;19:31. doi: 10.1186/s12877-019-1050-1
- 685 47. Life tables. In: World Health Organization; 2019.
- 686 48. Deaths by main cause of death. In: Statistics Netherlands(CBS); 2019.
- 49. Vaartjes I, O'Flaherty M, Capewell S, Kappelle J, Bots M. Remarkable decline in ischemic stroke
 mortality is not matched by changes in incidence. *Stroke*. 2013;44:591-597. doi:
 10.1161/STROKEAHA.112.677724
- 50. Vaartjes I, Reitsma JB, de Bruin A, Berger-van Sijl M, Bos MJ, Breteler MM, Grobbee DE, Bots
 ML. Nationwide incidence of first stroke and TIA in the Netherlands. *Eur J Neurol*.
 2008;15:1315-1323. doi: 10.1111/j.1468-1331.2008.02309.x
- 51. Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N, Poci D.
 All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a
 Swedish nationwide long-term case-control study. *Eur Heart J.* 2013;34:1061-1067. doi:
 10.1093/eurheartj/ehs469
- 697 52. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S,
 698 Bailleul C, et al. Subclinical atrial fibrillation and the risk of stroke. *N Engl J Med.* 2012;366:120-

699 129. doi: 10.1056/NEJMoa1105575 700 53. Chang ET, Lin YT, Galla T, Clayton RH, Eatock J. A Stochastic Individual-Based Model of the 701 Progression of Atrial Fibrillation in Individuals and Populations. PLoS One. 2016;11:e0152349. 702 doi: 10.1371/journal.pone.0152349 703 54. Khurshid S, Chen W, Singer DE, Atlas SJ, Ashburner JM, Choi JG, Hur C, Ellinor PT, McManus 704 DD, Chhatwal J, et al. Comparative Clinical Effectiveness of Population-Based Atrial Fibrillation 705 Screening Using Contemporary Modalities: A Decision-Analytic Model. J Am Heart Assoc. 706 2021;10:e020330. doi: 10.1161/JAHA.120.020330 707 55. Diederichsen SZ, Haugan KJ, Kronborg C, Graff C, Hojberg S, Kober L, Krieger D, Holst AG, 708 Nielsen JB, Brandes A, et al. Comprehensive Evaluation of Rhythm Monitoring Strategies in 709 Screening for Atrial Fibrillation: Insights From Patients at Risk Monitored Long Term With an 710 Implantable 2020;141:1510-1522. Loop Recorder. Circulation. doi: 711 10.1161/CIRCULATIONAHA.119.044407 712 56. Lubitz SA, Atlas SJ, Ashburner JM, Lipsanopoulos ATT, Borowsky LH, Guan W, Khurshid S, 713 Ellinor PT, Chang Y, McManus DD, et al. Screening for Atrial Fibrillation in Older Adults at 714 Primary Care Visits: VITAL-AF Randomized Controlled Trial. Circulation. 2022;145:946-954. 715 doi: 10.1161/CIRCULATIONAHA.121.057014 716 57. Gruwez H, Verbrugge FH, Proesmans T, Evens S, Vanacker P, Rutgers MP, Vanhooren G, 717 Bertrand P, Pison L, Haemers P, et al. Smartphone-based atrial fibrillation screening in the general

718 population: feasibility and impact on medical treatment. Eur Heart J Digit Health. 2023;4:464-719 472. doi: 10.1093/ehjdh/ztad054

720



724 Figure 1. Schematic model overview and examples of AF episodes and clinical outcomes in virtual 725 individuals simulated by the patient-level model. A, Patient-level model with 7 clinical states 726 including sinus rhythm, symptomatic AF, and asymptomatic AF, each with or without previous stroke, 727 as well as death. Transition probabilities were age/sex dependent. AF-related remodeling was also

722

728 incorporated in the model as function of the time in AF, and modulated the likelihood of AF 729 development, cardioversion, and the occurrence of stroke and death. B, Representative example of a 730 patient with multiple AF episodes and AF progression during the 100-year follow-up (Top) and 731 expanded view of the interval from 67 years to 68 years of age during which paroxysmal AF 732 progressed to persistent AF (Bottom). C, Representative example of a patient with multiple AF 733 episodes and incident stroke during the 100-year follow-up (Top) and expanded view from 80 years to 734 81 years of age during which the stroke event occurred (yellow-shaded area). A single column in panels 735 B, C represents one month and one day in the upper and lower panels, respectively.





Figure 2. Comparison of population-level atrial fibrillation (AF) metrics in 10,000 virtual individuals to epidemiological data. A-B, Age dependence of the prevalence (A) and incidence (B) of clinical AF in model (black line) and different clinical studies (colored lines).²⁴⁻³⁶ Sex-specific AF prevalence and incidence are shown in Figure S4. C, The proportion of paroxysmal AF (pAF) and nonparoxysmal AF in virtual patients with a clinical diagnosis of AF compared to clinical data from Nieuwlaat et al.⁴⁰ D, The proportion of symptomatic AF patients in the model compared to Gibbs et al.³⁹





747 Figure 3. Comparison of episode-level atrial fibrillation (AF) metrics and AF progression in the 748 patient-level model to rhythm-monitoring data in AF patients. A-C, Frequency (A), maximum 749 episode duration (B) and AF burden (C) during a 12-day follow-up period in patients with paroxysmal

- 750 AF compared to Wineinger et al.⁸ D-E, Mean age (D) and median AF burden (E) in different AF
- burden groups defined by the RACE-V study.¹⁹ **F**, The proportion of symptomatic AF episodes from all
- virtual patients with AF compared to implantable cardiac monitor data.⁴¹ G-H, Yearly progression rate
- 753 from paroxysmal to non-paroxysmal AF (G) or AF burden progression rate (H) compared to data from
- the RACE-V study.²⁰ I, AF recurrence rate after spontaneous cardioversion in patients with early phase
- AF, as defined by the different clinical trials.^{21,43,44}



757 Figure 4. Comparison of clinical outcomes in 10,000 virtual patients to epidemiological data. A,

758 Mortality across different age groups in the virtual cohort compared to the data from WHO.⁴⁷ B.

Percentage of deaths across different age groups in the virtual cohort compared to the data from 759

Statistics Netherlands.⁴⁸ C-D, Stroke incidence (C) and percentage of strokes (D) across different age 760 groups in the virtual cohort compared to the data from Modig et al.⁴⁶ E, Mortality in patients with 761

clinical AF compared to age- and sex-matched patients in model and data from Andersson et al.⁵¹ F, 762

763 Cumulative stroke rate in patients with or without any AF episodes compared to the continuous

monitoring data from ASSERT study.⁵² G, Validation of stroke risks in patients with different durations 764

765 of subclinical AF compared to patients with no subclinical AF in the model compared to data from the

766 ASSERT study,¹⁸ which were not used for model development and calibration.



768

769 Figure 5. AF screening in 10,000 virtual patients with or without continuous rhythm monitoring 770 (CRM) and schematic illustration of self-defined AF screening protocols. A-B, Cumulative stroke 771 rates (A) and AF detection rates (B) with or without CRM in the virtual cohort compared to data from

- patients with implanted loop recorders from the LOOP trial.⁹ C-E, Schematic illustration of self-
- defined systematic AF screening (C), symptom-based long-term (until death, D) or short-term (2
- 774 weeks, E) AF screening.



775 776

777 Figure 6. Stroke rates in populations with or without AF screening. A, Comparison of 5-year and 778 25-year stroke rates in populations with normal baseline stroke risk and different AF screening 779 strategies. B, The 5-year and 25-year relative stroke reduction for AF screening groups with normal 780 baseline stroke risk and anticoagulation therapy with 70% efficacy, compared with the control group. 781 Here, systematic screening means AF screening initiated for everyone from 65 years to death, and 782 symptomatic screening means AF screening initiated from the 1st symptomatic AF episode after 65 783 years to death. The diagnostic criterion for clinical AF was 3 hours of symptomatic AF. See Methods 784 for details.



🛏 At 5 years 🔸 At 25 years

785 786

787 Figure 7. Sensitivity analysis of the impact of different healthcare factors on relative stroke risk

reduction induced by AF screening. A-C, The 5-year and 25-year relative stroke reduction for AF
 screening groups with increased efficacy of anticoagulation therapy (90% less stroke compared with

the control group (A), 3-fold increase in baseline stroke risk (B), or with a diagnostic criterion of

- 791 clinical AF of 24 hours symptomatic AF (C). Abbreviations of different screening strategies are the
- same as in **Figure 6**.

% of patients benefitting from screening (n/ AF cases possibly at benefit*)	% of screening- detected AF [†] (n/ AF cases possibly at benefit)	% of earlier – detected AF [‡] (n/ AF cases possibly at benefit)	# of days ahead of clinical AF diagnosis [§] for earlier-detected AF (n, IQR)						
Continuous AF screening (systematic or long-term symptom-based)									
99.7%	31.6%	68.1%	720 (140, 1448)						
(3524 / 3534)	(1118 / 3534)	(2406 / 3534)							
52.5%	8.0%	44.6%	390 (94, 813)						
(1852 / 3525)	(281 / 3525)	(1571 / 3525)							
Systematic AF screening (all participants from 65y to death)									
4.7%	4.7%	0.03%	516						
(165 / 3491)	(164 / 3491)	(1 / 3491)							
64.6%	17.2%	47.4%	301 (9, 697)						
(2268 / 3511)	(603 / 3511)	(1665 / 3511)							
16.7%	8.6%	8.2%	248 (53, 605)						
(588 / 3514)	(301 / 3514)	(287 / 3514)							
23.3%	10.4%	12.9%	285 (66, 718)						
(818 / 3517)	(365 / 3517)	(453 / 3517)							
symptom-based AF s	screening (from the 1	st symptomatic AF a	fter 65y, for 2w)						
0.2%	0%	0.2%	428 (163, 558)						
(8 / 3539)	(0 / 3539)	(8 / 3539)							
0.5%	0%	0.5%	100 (36, 277)						
(26 / 3517)	(0 / 3517)	(26 / 3517)							
0.6%	0.06%	0.5%	218 (107, 647)						
(20 / 3400)	(2 / 3400)	(18 / 3400)							
2.7%	0.4%	2.3%	279 (111, 610)						
(97 / 3583)	(16 / 3583)	(81 / 3583)							
mptom-based AF scr	<i>eening</i> (from the 1 st s	symptomatic AF afte	r 65y, until death)						
17.6%	1.6%	16.0%	183 (17, 410)						
(623 / 3530)	(58 / 3530)	(565 / 3530)							
35.1%	4.0%	31.1% (1078 / 3464)	204 (11, 551)						
(1217/3464)	(13) / 5404)	(10707 5404)							
	% of patients benefitting from screening (n/AF cases possibly at benefit*) Continuous AF screen 99.7% (3524 / 3534) 52.5% (1852 / 3534) 52.5% (1852 / 3534) 52.5% (1852 / 3534) 52.5% (1852 / 3534) 64.6% (2268 / 3511) 16.7% (588 / 3514) 23.3% (818 / 3517) symptom-based AF scr 0.2% (8 / 3539) 0.5% (26 / 3517) 0.6% (20 / 3400) 2.7% (97 / 3583) mptom-based AF scr 17.6% (623 / 3530) 35.1% (1217 / 3464)	% of patients benefitting from screening (n/ AF cases possibly at benefit*)% of screening- detected AF (n/ AF cases possibly at benefit)Continuous AF screening (systematic or let 99.7% 31.6% ($3524/3534$) 31.6% ($1118/3534$)52.5% 8.0% ($1852/3525$) 8.0% ($281/3525$)Systematic AF screening (all participa 4.7% ($165/3491$) 4.7% ($164/3491$) 64.6% ($1588/3514$) 17.2% ($2268/3511$) 63.6% ($588/3514$) $301/3514$) 23.3% ($818/3517$) 10.4% ($365/3517$)symptom-based AF screening (from the 1 0.2% ($20/3400$) 0% ($2/3400$) 2.7% ($97/3583$) 0.4% ($16/3583$)mptom-based AF screening (from the 1st st 17.6% ($1217/3464$) 1.6% ($139/3464$)	% of patients benefitting from screening (n/AF cases possibly at benefit)% of screening- detected AF (n/AF cases possibly at benefit)% of earlier - detected AF (n/AF cases possibly at benefit)Continuous AF screening (systematic or long-term symptom-I 99.7% 31.6% $(3524 / 3534)$ 68.1% $(2406 / 3534)$ 52.5% (3524 / 3534) 8.0% $(1118 / 3534)$ 44.6% $(1852 / 3525)$ $281 / 3525)$ Systematic AF screening (all participants from 65y to deat4.7% (165 / 3491) 17.2% $(164 / 3491)$ 47.4% $(1 / 3491)$ 64.6% (2268 / 3511) 17.2% $(603 / 3511)$ 47.4% $(2268 / 3511)$ 16.7% (818 / 3517) 8.6% $(365 / 3517)$ 8.2% $(453 / 3517)$ symptom-based AF screening (from the 1st symptomatic AF at 0.2% $(26 / 3517)$ 0.06% 0.5% $(26 / 3517)$ 0.2% 0% 0.5% 0.5% $(20 / 3400)$ 0.4% $(2 / 3400)$ 2.3% $(16 / 3583)$ 0.6% 0.5% $(20 / 3400)$ 2.7% 0.4% 0.6% 0.5% mptom-based AF screening (from the 1st symptomatic AF at 17.6% $(16 / 3583)$ 1.6% $(16 / 3583)$ 0.5% $(21 / 3400)$ 2.7% $(27 / 3583)$ 0.4% $(16 / 3583)$ 2.3% $(16 / 3583)$ 1.6% $(162 / 3530)$ mptom-based AF screening (from the 1st symptomatic AF after 17.6% $(127 / 3664)$ 1.6% $(139 / 3444)$ $1078 / 3444$						

793 Table 1. AF detection rates of different screening protocols applied in the virtual cohort

	Yearly 14d Holter	12.0% (429 / 3563)	1.2% (41 / 3563)	10.9% (388 / 3563)	229 (37, 507)					
794										
795	Results are presented as absolute numbers with percentage or median numbers with quartiles.									
796	* AF cases possibly at benefit are those with ANY AF episodes during LIFETIME follow-up and									
797	still alive at 65 years of age (i.e., start of screening) without clinical AF diagnosis (= the number									

798 of total AF cases within 100 years - AF cases died before 65y - clinical AF cases before 65y)

799 [†] Screening-detected AF are patients detected by screening protocols ONLY

800 ‡ Earlier-detected AF are patients detected by screening protocols earlier than their clinical AF 801 diagnosis

802 § Clinical AF was diagnosed when the first symptomatic AF episode lasted \geq 3 hours